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INTRODUCTION
Experimental allergic encephalomyelitis (EAE) is an
acute neurological autoimmune disease induced in a variety
of species by injection of brain or spinal cord tissue in
complete Freund’s adjuvant (Patterson 1971,1977)
The active encephalitogenic component in central
nervous system (CNS) tissue has been identified as the
basic protein of myelin (MBP) (Einstein et al., 1962)
Different amino acid sequences of a given MBP molecule are
recognized as the maj or encephalitogenic determinant in
various species, with pronounced species variability (Chao
and Einstein, 1970; Shapira et al., 1971; Chou et al.,
1977; Kibler et al., 1977; Pettinelli et al., 1982; Fritz
et al., 1983) Using different techniques, at least eight
distinct antigenic determinants for delayed type hyper-
sensitivity and three for antibody production were shown
in the protein, but they do not correlate with the regions
responsible for the encephalitogenicity (Driscoll et al.,
1974)
EAE is characterized by a variety of clinical
manifestations, mainly paralysis which culminates sometimes
in death, and with histopathologic changes consisting of
focal areas of intense perivascular cellular infiltration,
consisting mainly of T lymphocytes (helper/inducer subset)
(Pettinelli and MacFarlin, 1981; Sriram et al., 1982;
Dialynas et al., 1983; Lando and Ben-Nun, 1984; Wekerle,
1984; Trotter et al., 1985) Although controversy exists
concerning the role of antibodies in the pathogenesis of
EAE, there is convincing evidence for the involvement of
cell-mediated immune reaction towards MBP that parallels
the induction of the disease. The most important clue is
the transfer of clinical disease by MBP sensitive T cells.
In both rats and mice it has been shown that the T cell
population is responsible for this function (Ortiz and
Weigle, 1976)
In view of the immunological nature of EAE, attempts
have been made in several laboratories to prevent, reverse
or suppress the disease in animals challenged with MBP.
This has been attempt by desensitization procedures using
the specific antigens relevant to the system (Arnon and
Teitelbaum, 1980) by using monoclonal antibodies to the
L3T4 (helper cell) surface marker (Waldor et al., 1985)
and by using immunosuppressive treatment with
cyclosporine A (Ryfell et al. 1982; Bolton et al., 1982;
Fredane et al., 1983; Hinrich et al., 1983; Borel et al.,
1986; Shuller-Levis et al., 1986; Ellerman et al., 1988).
However, there is a lack of information regarding
immunospecific therapy and immunoregulation in murine EAE
dealing with suppressor cell control of the autoaggressive
lymphocyte clones. Furthermore, establishment of sup-
pressor T cell lines could prove to be a suitable thera-
peutic approach.
Therefore, the present study attempts to generate in
vitro T cell clones or lines specific for MBP-specific T
cell and to examine the ability of these T anti-T cell
clones or lines to inhibit the passive transfer of disease
by MBP-specific T clones or lines.
REVIEW OF THE LITERATURE
I. Historical
In 1885, Pasteur introduced his vaccine for
prevention of rabies (Patterson, 1977). He stated that
the vaccine consisted of brain infected with a strain of
rabies virus that had been attenuated or fixed by repeated
passage in rabbits. Patients bitten by dogs suspected of
having rabies received repeated injections of the vaccine
in efforts to induce active immunity to virulent or
"street" rabies virus. Acute neurological disease
developed in occasional subjects receiving a course o f
vaccine prophylaxis. By 1888, it was clear that these
"neuroparalytic complications" represented an acute
inflammatory process of the CNS, i.e., encephalitis,
myelitis, or encephalomyelitis. Increasing suspicion
during the 1920 s that post-rabies vaccinal encephalo-
myelitis was an allergic reaction to nervous tissue
antigens accelerated studies in experimental animals
related to the immunogenic potential of mammalian tissues.
By 1928, Witebsky and Steinfeld showed that the brain
tissue contained specific antigenic constituents which
stimulated antibodies specifically reactive with CNS
tissue.
It remained for Rivers et al. (1933 and 1935) to
discover that an acute disseminated encephalomyelitis
could be produced in monkeys receiving repeated injection
of nervous tissues extracts or emulsions over a period of
many weeks or months which resembled post-rabies vaccinal
encephalomyelitis. This finding was confirmed by Ferraro
and Jervis (1940) who introduced rabbit brain into monkeys
29 to 103 times over a period of 112 to 405 days. The
animals first showed neurological signs after 3 to 13
months. Ferraro (1944) concluded that the reaction in the
nervous system was of an allergic nature a view which
found active support so that the experimental disease was
called "allergic" (or isoallergic) encephalomyelitis.
Another advance was gained by the addition to brain
tissue of what was known as the "Freund adjuvant" for the
purpose o f bringing about experimental disease more
rapidly and regularly. Freund and McDermott 1942
demonstrated that a mixture of lanolin-like substances,
paraffin oil, and killed tubercle bacilli, induced a
prompt and high antibody response when added to a wide
variety of antigens. Thus, in 1947 Freund et al. Morgan;
Kabat et al. and Morrison simultaneously reported that a
single injection of nervous tissue emulsified in complete
Freund’ s adjuvant (CFA) (containing mycobacteria)
regularly induced an accelerated and extremely severe form
of disseminated encephalomyelitis in guinea pigs, monkeys,
and rabbits within a matter of 2 or 3 weeks.
The experimental production of neurological signs
and lesions in different animals, however, was unpre-
dictable. Later, Olitsky and Yager (1949) showed however
that mice, when immunized with CNS tissue incorporated
with a modified adjuvant, were ill sooner with fewer
exposures than the other species of animals.
Ii. The Role of Myelin Basic Protein Reactive T Cells
There was ample evidence that induction of EAE by the
injections of CNS tissue results in the generation of both
antibodies and cell-mediated immunity. However contro-
versy existed concerning the role of antibodies in the
pathogenesis of EAE. Thomas et al. (1950); Lumsden et
al. (-1950) found a poor correlation with titers of
circulating brain antibodies. Patterson (1977) was not
able to transfer the disease to normal animals with immune
serum but it was found to be possible to transfer the
disease by one inoculum of sensitized lymphoid cells.
Arnason et al. 1962 showed that neonatally
thymectomized rats had a markedly reduced capacity to
develop EAE. This finding was difficult to interpret
because such animals also were compromised with respect to
production of antibody. A single report by Blaw et al.
(1967) that EAE occurred in chickens rendered hypo or
aggamaglobulinemic by prior extirpation of the bursa o f
Fabricius was difficult to interpret because of the small
number of birds that were truly aggamaglobulinemic.
Gonatas and Howard (1974) were the first to secure
definitive evidence that T cells were a prerequisite for
development of EAE in rats. Adult Lewis rats were
thymectomized, subjected to total body irradiation, and
reconstituted with bone marrow cells from thymectomized,
thoracic duct-drained donors, thereby assuring that no T
cells were represented in the bone marrow suspension.
Such rats were totally lacking in their capacity to
develop EAE following sensitization to guinea pig spinal
cord or MBP- CFA. Absence of MBP-binding antibody
indicated that the rats were deficient in T cells
collaborating with antibody- producing B cells. The
absence of helper T cells provided indirect evidence that
the rats were truly depleted of all T cell subpopulations
but left the question of whether antibody might have a
role in the disease.
The studies of Ortiz-Ortiz and Weigle (1976) and
Ortiz "et al. (1976) have provided compelling evidence that
a specific T cell sub-population causes EAE. They found
that EAE could not be induced in thymectomized rats, but
that grafting of thymus cells restored susceptibility to
EAE following priming with MBP. However, they were unable
to transfer clinical EAE after depleting T cells with
anti-T cell antiserum, although they were able to induce
anti-MBP antibodies. EAE could be transferred to T cell
deficient nude rats by injection with immune cells from
syngeneic EAE donor rats (Hinrichs and Humphries, 1983)
Finally, EAE has been induced by the transfer o f
encephalitogenic T cell lines and clones (Ben-Nun et al.,
1981; Ben-Nun and Lando, 1983; Trotter et al., 1985).
Results of several studies using immunohistologic
analyses of the infiltrating cells in acute EAE, had
established that the predominant cell of the early acute
EAE lesion was the T lymphocyte. Furthermore, the
predominant T cell population belonged to the helper/
inducer
in the
subset which was characterized by the W3/25 marker
rat (Wekerle, 1984 and by Lyt- 1+ 2- and L3T4
determinants in the mouse (Pettinelli and MacFarlin, 1981;
Sriram et al., 1982; Dialynas et al., 1983; Lando and Ben-
Nun, 1984 Trotter et al., 1985) However, cytotoxic /
suppressor (or precursor) Lyt-2+ T cells as well as B
cells were present at lower frequencies 10% and 12%
respectively) (Sriram et al., 1982) B cells and
macrophages appeared at later stage, 10 days
post-inoculation with bovine white matter and CFA, and
were restricted to the meninges and perivascular spaces.
On the other hand, T cells were demonstrable as early as 5
days post-inoculation, before the onset of clinical signs
and w@re predominantly found within the CNS parenchyma of
guinea- pigs (Traugott et al., 1982).
A neuropathological study of EAE (MacKay et al.,
1973 emphasized the many similarities between the
histopathological hallmarks of the experimental animal
disease and those characterizing multiple sclerosis (MS)
in man. This was especially true in those forms of the
human disease that were characterized by an acute or
subacute course leading to death
period of time. However, chronic
in a comparatively short
and relapsing forms of
EAE also had similarities to MS (Wisniewski et al., 1977,
Raine et al., 1974) Mocktarian et al. (1984) reported
that a single transfer of MBP-sensitized lymph node cells
or T cells, in the absence of a peripheral antigen depot,
led to both acute EAE with significant primary
demyelination, and chronic relapsing disease with the
lesions typical of demyelination over a long period.
Zamvil et al. (1985) generated MBP-specific T-cell clones
restricted to class II (Ia) antigens of the maj or
histocompatibility complex (MHC) from PL/J and (PL/SJL)F 1
mice following sensitization to rat MBP. Two such
IaU-restricted T-cell clones that proliferated in response
to the encephalitogenic N-terminal MBP peptide and
recognized a shared determinant with mouse (self) MBP
caused paralysis in 100% of (PL/SJL) F 1 mice tested.
Relapsing paralysis followed in two-thirds of the
recipients after recovery from acute paralysis, whereas
one third developed chronic persistent paralysis. These
findings had maj or implications for the immunological
mechanisms involved in experimental and human
demyelinating diseases, reinforcing the view that EAE was
a meaningful laboratory model for MS.
I0
In summary, the autoimmune nature of EAE can be
established by several criteria- I) the tissue damage
which followed the injection of the CNS material was
restricted to this tissue; and 2) sensitized lymphocytes
were capable of transferring the disease to normal
recipients.
III. Induction of EAE
EAE can be induced in a two diferent ways- by active
induction and by passive induction.
a) Active induction
This is accomplished in a variety of species by
injection of CNS antigens, mainly MBP (Levine and Wenk,
1961; Patterson and Bell, 1962; and Laatsch et al., 1962).
The induction leads to a severe inflammation of the CNS
white matter within i0 to 15 days (Levine and Wenk, 1961;
Patterson and Bell, 1962)
b) Passive induction
This is accomplished by transfer of encephalito-
genic MBP-reactive T-cell lines or clones into naive mice
or rats (Ben-Nun et al., 1981 and 1983; Naparstek et al.,
1983 and Pettinelli and McFarlin, 1981) Here, the
inflammation of the CNS white matter usually occurrs
within 5 to 8 days.
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Studies of Myelin Basic Protein
The discovery that MBP was responsible for a major
portion of the encephalitogenic activity of CNS tissue
(Einstein et al., 1962) opened the doors for a large
amount of research on this antigenic constituent.
MBP represents approximately one-third of the total
protein of myelin and about 1% of the weight of the whole
nervous tissue. It is extracted from delipidated mammalian
brain or spinal cord at acid pH ranges of 1.0-2.5, and can
be purified by various combinations of resin-gel chroma-
tography (Rauch and Einstein, 1974) Even the most "pure"
MBP preparations, however, reveal varying degrees o f
microheterogeneity (Chou et al., 1976) This
microheterogeneity may well account for differences in
specific activity of MBP preparations reported by
different laboratories. MBP is a heat-stable,
acid-resistant, relatively flat molecule with a molecular
weight in the range of 18,000-22,000 daltons (Rauch and
Einstein, 1974) Amino acid sequencing has revealed
about 170 residues for all MBP preparations derived from
nervous tissue of all mammalian species, except in rats.
Rat MBP has in addition to a 170-residue molecule, a
smaller molecular weight species MBP lacking a 40-amino
acid sequence comprising the carboxyl terminal position of
the parent molecule (Matersen et al., 1972).
The myelin basic protein molecule has been charac-
terized by using limited pepsin digestion. This cleaves
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the MBP into 3 fragments, consisting of amino acid 1 to
37, 38 to 87 and 88 to 170 (Chou et al., 1977). It has
been found that the ability of the fragments to induce EAE
differs among species and strains within a species. For
example, in the rat, the encephalitogenic determinant is
located within the peptide encompassed by residues 68-88
(Chou et al., 1977 and Kibler et al., 1977). Pettinelli
et al. (1982) has shown both by direct immunization and by
passive transfer experiments that a major encephalitogenic
determinant for the SJL/J mouse is located in the carboxy
terminal end at 89-170 of guinea pig myelin basic protein
(GPMBP). However, in subsequent studies (Fritz et al.,
1983) it was found that in the PL/J mouse strain, the
encephalitogenic determinant is situated within the amino
terminal end (residues 1-37) of GPMBP. When intact GPMBP
was used, both PL/J and SJL/J mice developed EAE.
(SJL/PL)F 1 mice developed EAE with intact GPBP.
V. Genetic Studies of EAE
I t has been established that immune responses to
many antigens may be regulated by distinct immune
response (Ir) genes. Many such Ir genes are associated
with the maj or histocompatibility complex (MHC) of the
particular species and map within the I region. In
additon, Ir genes not linked to the MHC were also
demonstrated as influencing the immune response to a
variety of antigens (Gasser and Silvers, 1974; Benacerraf
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and Katz, 1975) Thus, the genetics of the immune
response is complicated and may involve several genes and
cooperation between genes (Dorf et al. 1974), and may also
vary between species (Gunther et al., 1976). Moreover,
the immune response to different determinants on the same
molecule may be under different genetic control (Maron et
al., 1973) Genetic differences in immune response may
also play an important role in susceptibility to a variety
of diseases, including autoimmune diseases, in both
animals and man. This was demonstrated also for EAE in
several species.
Genetic studies of EAE in rats demonstrated that the
genetic control was not identical in all strain combina-
tions. In one case (BN X Lewis), it was controlled by a
single autosomal gene which, although closely linked to
the MHC, was rather distinct from it (Williams and Moore,
1973, Gasser et al., 1973) In the other strain
combinations such as (BN X DA) it was completely
independent of the MHC (Gasser et al., 1975). Williams
and Moore 1973 concluded that an autosomal dominant
gene linked to the histocompatibility locus determined
susceptibility to EAE by acting as a immune response (Ir)
gene. Studies in mice yielded controversial results
concerning the role of the H-2 complex in susceptibility
to EAE. In the mouse some authors have shown linkage to
the H-2s and H-2b haplotype (Bernard, 1976 and Raine et
al., 1980), whereas others have been unable to confirm
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these observations (Levine and Sowinski, 1974; Montgomery
and Rauch, 1982; Lando et al., 1979)
Arnon, 198 I, studied the susceptibility to EAE in
various mouse strains and in their F 1 hybrids with the
reportedly susceptible strain SJL/J (Lando et al., 1979).
The results showed in the SJL/J strain 48% developed
clinical incidence of the disease and all mice showed
histological changes in the brain, but the F 1 hybrid of
SJL/J with the resistant strain BALB/c was found to be
much more sensitive to EAE than the parent strain SJL/J.
Crossing SJL/J with the congenic strains of BALB/c
(BALB/C3H and BALB.BI0) which were of the same genetic
background but differ in their H-2 complex, resulted in F 1
hybrids with high sensitivity to EAE. Similarly, the F 1
hybrid of SJL/J X NZB was very sensitive as manifested
both in severity and incidence of clinical and
histological disease. On
with DBA/2 which is H-2d as
C57BL/6J which is H-2b
the other hand, crossing SJL/J
is BALB/c and NZB, or with
as BALB.BI0, resulted in hybrids
which were less sensitive to EAE than the parental strain
SJL/J.
These results demonstrated that there was no pure
dominant Mendelian inheritance of susceptibility to EAE
mice.
To investigate the possible linkage of EAE suscep-
tibility to the H-2 s haplotype, Arnon (1981) tried to
induce the disease in two strains that possesed the H-2 s
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haplotype (ASW and BIOS, as well as in their F 1 hybrids
with BALB/c). In all these strain combinations he failed
to induce the disease. These results were compatible with
those obtained by Levine and Sowinsky (1974) but differed,
howeve’r, from the results of Bernard (1976). Arnon’s data
defenitely indicated that the susceptibility to EAE was
not dependent solely on the H-2 s.
Therefore, it can be summarized that there are at
least two categories of susceptibility/resistance genes
playing a role in EAE (Gunther et al., 1978, and Gasser et
al., 1975). One is related to the MHC and the other genes
is unrelated to the MHC (Kallen and Logdberg, 1982; Levine
and Sowinski, 1974 Linthicum and Frelinger 1982
identified one of these non-MHC genes as being a histamine
sensitization gene in the mouse.
VI. Immunomodulation of EAE
Resistance to EAE not only appears to be a
genetically determinant trait, but also can be acquired in
genetically EAE-susceptible rats. Susceptible Lewis rats,
which had spontaneously recovered from acute EAE, become
resistant to EAE induction by a later second injection of
MBP in complete Freund’s adjuvant (CFA) Injection o
myelin basic protein in incomplete Freund’ s adj uvant
(IFA), which does not induce EAE, renders the recipient
resistant to subsequent encephalitogenic treatments, and
even pretreatment with CFA without MBP has a protective
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effect (Kies and Alvord, 1958 Svet-Moldavsky et al.,
1959) Adda et al. (1977) found that resistance to EAE
could be transferred to naive recipients by lymphoid cells
from recovered or resistant rats. Arnon (1981) and Welch
et al. (1980) suggested that suppressor T cells, at least
in rats, were the key cells in self limitation of and
subsequent resistance to EAE.
There is significantly less known about the
mechanisms of resistance in the mouse than in the rat.
Lando et al. (1980) showed that hybridization between some
EAE-resistant mouse strains such as DBA/2 or CB57BL/6J and
the sensitive SJL/J resulted in crosses which exhibited
much less sensitivity than the parental strain. This was
indicative of a suppressive effect of the resistant
parent. To support that statement, Lando et al. (1979)
tested the effect of cyclophosphamide (CY) 2 days before
induction of disease in the susceptible mice SJL/J and
(SJL/J X BALB/c) FI, and no differences were observed in
the incidence or severity of EAE. On the other hand, CY
had a marked effect in a proportion of resistant strains
(Lando et al., 1980). The most dramatic effect was in
BALB/c mice, which after treatment with CY succumbed to
the disease to the same extent and with the same severity
as the susceptible SJL/J mice. However, in other
resistant strain such as DBA/2, CY had no effect on
disease induction. The dose of CY used was reported to
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eliminate specifically a population of T suppressor cells
in other systems (Chiorazzi et al., 1977).
An effect comparable to that exerted by the cyclo-
phosphamide could be obtained by other immunosuppressive
treatments, such as low dose irradiation (Chiorazzi et
al. 1976) Arnon 1981 observed that sublethal
irradiation with 350R, 2 days before the encephalitogenic
challenge, brought about development of EAE in 50% of the
BALB/c mice, which were otherwise resistant to the
disease. It can be concluded that CY or low dose
irradiation can convert one type of resistant strain into
a susceptible strain, while these treatments have no
effect on another type of resistant strain. It was
suggested that in strains of the first type a gene that is
responsible for susceptibility to EAE did exist but the
natural high level of suppressor cells in these strains
prevented the manifestation of disease. Following
treatment with CY these suppressor cells were eliminated
and disease was overt. Indeed, it was demonstrated
earlier by Lage-Stehr and Diamanstein (1978) that CY can
induce a transient appearance of "autoreactive" T
lymphocytes in spleens of mice. In NZB mice it has been
demonstrated that loss of effective suppressive T cell
function can lead to autoimmune diseases (Talal 1976).
This information support the conclusion that suppressor
cells may play a paramount role in both protection and
natural resistance to EAE.
18
The previous findings were of vital importance in
planning strategies for treatment of EAE. Numerous
attempts have been made to suppress the disease in animals
challenged with MBP antigen or with MBP-specific T cell
clones by desensitization procedures using the specific
antigens relevant to the system (Arnon and Teitelbaum,
1980); by giving monoclonal antibodies to the MHC I region
products (Steinman et al., 1981, and Sriram and Steinman,
1983) or by giving monoclonal antibodies to the L3T4
surface marker (Waldor et al. 1985 and by using
immunosuppressive treatment with Cyclosporine A (Rifell et
al., 1982; Bolton et al., 1982; Fredane et al., 1983;
Hinrich et al., 1983; Borel et al., 1986; Schuller-Levis
et al., 1986). It has been shown (Alvord et al., 1965;
Einstein et al., 1968) that MBP, if given in high doses in
incomplete Freund s
preventing EAE in
adjuvant, was highly effective in
guinea pigs when administered before
sensitization or in suppressing EAE if given after
sensitization. However, not only the encephalitogenic
protein was effective in treatment and prevention, but
other non-encephalitogenic related peptides or other
antigens had a similar protective effect. Thus, the
course of EAE was found to be modified by myelin
non-encephalitogenic basic proteins (Einstein et al.,
1968) altered MBP (Swanborg, 1972 Einstein et al.,
1972) and non-encephalitogenic degradation products
(Swanborg, 1975) or synthetic fragments of MBP (Teitelbaum
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et al., 1971; Teitelbaum et al., 1973; Teitelbaum et al.,
1974; Webb et al., 1976; Hashim et al., 1976; Teitelbaum
et al., 1977; Lando et al., 1979; Keith et al., 1979).
Reversal of EAE has been attempted in vivo in the
mouse by using monoclonal antibodies to Ia antigens or to
the L3T4 surface marker. Steinman et al. (1981) showed
that in vivo administration of antibodies reactive with
I-As gene products prevented the induction of EAE in the
SJL/J mouse when tratment was instituted prior to
immunization with MBP. However EAE was delayed, but not
prevented, when antibody was administered 5 days after the
immunization. The suppressive effect of anti-I-A
antibodies on EAE induction may work by blocking APC
presentation of the encephalitogenic MBP determinant to T
cells. Sriram and Steinman (1983) extended the same study
in cases of acute and chronic relapsing EAE by instituting
treatment at the onset of paralytic signs and then
following the clinical course. In chronic relapsing EAE,
animals treated with anti-I-As antibody had no mortality
and fewer relapses when compared with control animals.
Similarly, in the acute EAE model, animals treated with
anti-I-As antibody showed a dramatic reversal of paralytic
signs and a rapid recovery.
Waldor et al. (1985) gave mice monoclonal antibodies
(GKI.5) that recognize the L3T4 marker present on helper T
cells and were able to reduce the number of L3T4+ cells in
the spleen and the lymph nodes. This treatment also con-
2O
sequently prevented EAE when GKI.5 was administered before
the onset and shortly after the first symptoms of EAE
appeared. However, treatment of quadriplegic or moribund
mice (advanced stage) did not ameliorate paralysis or
prevent death. The efficacy of monoclonal antibody
therapy in treating diseases may, however, be limited by
the development by the host of anti-idiotypic antibodies
directed towards the therapeutic monoclonal antibody.
Consequently, the use of suppressor T cell clones rather
than monoclonal antibodies, may be less susceptible to
such regulation.
The fungal metabolite cyclosporine A (CSA), which is
a very hydrophobic, cyclic endecapeptide (Petcher et al.,
1976) is known to exert powerful immunosuppressive effects
(Cyclosporine A, Intern. Symposium, 1981 CSA-induced
immunosuppression is most effective on T-cell-mediated
immune responses (Wiesinger and Borel, 1979) Although
the mode of action of CSA is still under study, it has
been shown to suppress interleukin-2 (IL-2) production
(Thompson et al., 1983; Shidani et al., 1984; Reem et al.,
1983) and appears to act selectively by inhibiting IL-2
mRNA (Granelli-Piperno et al., 1984)
CSA has been shown to suppress EAE in rats (Borel et
al., 1986, Ryfell et al., 1982, Bolton et al., 1982)
guinea pigs (Bolton et al., 1982, Fredane et al., 1983),
and rhesus monkeys (Bolton, 1981) if given during the
sensitization phase. In addition to this prophylactic
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effect, CSA also has a strong therapeutic effect in rats
when administration is started at the onset of the
symptoms. The treated animals recovered more quickly than
the controls, but there was often a relapse when treatment
was discontinued. Similar results were obtained in the
guine pig (Fredane et al., 1983).
In the passive transfer of EAE in the rat, if the
donors cells are activated in vitro with specific antigen
or mitogen in the presence of CSA for 72-hour, prolifera-
tion of the donors cells is considerably suppressed, and
both clinical and histological disease after passive
transfer with such cells is decreased (Ryffel et al.,
1982; Bolton et al., 1982; Hinrichs et al., 1983).
Recently, Ellerman et al. (1988) were able to isolate
a distinct population of cells with suppressor activity by
culturing T cell lines generated from Lewis rats immunized
one month before with GP-MBP. These cell lines were grown
with GP-MBP and cyclosporine A for 1-7 days and after 5 to
6 cycles of subsequent antigen stimulation, the cells
produced mild clinical signs of disease, which decreased
with subsequent cycles of antigen stimulation. Most
importantly, adoptive transfer using an encephalitogenic T
cell line was prevented by the co-transfer of this
"suppressor line".
CSA has also been used to treat an induced acute
attack after disease onset and remission in chronic
relapsing EAE in SJL/J mice (Schuller-Levis et al., 1986).
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CSA led to a dose-dependent decrease in the length and
severity of attack and significantly lower mortality in
the CSA-treated mice compared to the non-CSA-treated mice.
In addition, there was decreased production o the
lymphokine, lymphocyte-derived chemotatic factor (LDCF)
in the cyclosporine treated mice.
Jerne (1974) has developed a "network" theory in
which immune regulation results from lymphoid cell
receptors recognizing determinants on the other lymphoid
cell eceptors. According to this hypothesis, it may be
possible to generate regulatory suppressor or cytotoxic T
cell clones against helper T cells. Lamb and Feldmann
(1982) in humans, have shown the feasibility of generating
suppressor T cell clones specific for a helper T
lymphocyte which recognizes influenza A matrix protein in
the absence of APC. Such an autologous suppressor cell
clone recognizes and inhibits the activation of this
helper T cell clone. Thus, situations in which there are
undesirable clones of helper (or Killer) cells such as
autoreactive MBP-specific T cell clones may be
controllable by suppressor cells of this type, generated
in vitro.
Mohagheghpour et al. (1986) showed in humans that
+CD8 T cells proliferated upon exposure to autologous,
antigen- primed CD4 + T cells, and supressed the response
of fresh T cells to
irrelevant antigens.
the priming antigen but not to
The CD8+ cells inhibited the
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response of fresh autologous T cells only to the original
allogeneic stimulator cell and to stimulator cells that
shared HLA-DR antigens with the priming cell.
Such T-T cell interactions have not been extensively
studied in the mouse. Suzuki et al. (1986) showed that
resting T cells could proliferate in response to T cell
blasts, but were inhibited by anti-Ia antibodies. This
inhibition was surprising in that" a) these T-T cell
interactions could occur in the absence of APC, and b)
murine T cells do not express la antigens. These authors
postulated that perhaps the T cells were passively
acquiring Ia antigens on their surface and that these Ia
antigens were then serving as determinants being
recognized either alone or in conjunction with other
surface determinants.
Sun et al. (1988) isolated homogeneous T lymphocyte
lines from spleens of Lewis rats that had recovered from
T-cell-mediated EAE caused by the MBP-specific T cell line
S l. These spleen-derived anti-Sl T cell lines expressed
the CD8-determinant and proliferated against the S1 line.
The anti-Sl lines were strictly specific for markers on S1
line cells and were not reactive to MBP. In addition, the
anti-Sl cells lysed the encephalitogenic S1 T line in
vitro and efficiently neutralized their encephalitogenic
capacity in vivo.
The generation of cells with suppressor activity in
EAE has been described in rats, but the generation of
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murine T cell anti-T cell clones or lines with suppressor
activity has not been previously demonstrated in murine
EAE.
OBJECTIVES OF THIS STUDY
I. General Objectives
There is substantial evidence in the literature that
EAE is mediated by myelin basic protein (MBP) specific T
cells, and that, at least in the rat, the severity or
recovery from the clinical syndrome is regulated, at least
in part, by the generation of a population of "suppressor"
T cells.
Therefore, this study sought to generate murine
clones or lines of T cells that could regulate the
mediation of EAE by MBP-specific lines or clones. The
sensitization protocol, cell cloning and passive transfer
techniques are well established and feasible. However,
the generation of murine T cell anti-T cell clones or
lines with "suppressor" activity has not previously been
accomplished. The suppressor clones or lines raised
against the MBP-reative clones could be directed against
the MBP antigen-receptor, or against another cell surface
antigen. In any case, the "regulatory" T cell lines or
clones generated in vitro, will also be tested in vivo for
the ability to inhibit the passive transfer of EAE by MBP-
specific T cells.
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Specific Obj ectives
i. To generate, "in vitro", murine T cell clones or
lines specific for MBP-specific T-cell lines
capable of mediating experimental allergic
encephalomyelitis.
2. To characterize these T anti-T cells for cell
surface phenotype.
3. To examine "in vivo", regulatory effects of
murine T-clones or lines specific for
EAE-mediating T cell lines.
MATERIALS AND METHODS
I Cloning of EAE-inducing Cells
a) Myelin basic protein-sensitization
Male and female SJL/J mice, ages 4 to 8 weeks
(obtained from the National Institutes of Health), were
injected in the hind foot pads with 0.I ml containing i00
to 250 micrograms total per mouse) of porcine MBP
(Calbiochem, La Jolla, CA) emulsified in an equal volume
of complete Freund’s adjuvant (supplemented with 6 mg/ml
of desiccated Mycobacterium tuberculosis H37 RA (Difico
Laboratories, Detroit, MI) This sensitization was
followed at 24 and 72 hours by an i.v. injection of
2.2xl 010 formalin fixed, washed Bordetella pertussis
organisms (Michigan Department of Health) Sensitized
mice were sacrificed by exsanguination via cardiac
puncture under ether anesthesia i0 days after the
injection of MBP.
b) Lymph nodes cell culture
Popliteal and inguinal lymph nodes were removed
from SJL/J mice i0 days after immunization with porcine
MBP and CFA in both hind foot pads. These lymph nodes
were put into single cell suspension over nylon mesh
screens and subsequently cultured for 3 days with porcine
myelin basic protein (PMBP) (i0 Dg/ml) or PPD (15 Dg/ml)
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in the absence of interleukin-2 (IL-2) These cultures
were established in complete media" RPMI 1640 (Biofluids,
Bethesda, MD) with penicillin (I00 mg/ml) streptomycin
(i00 zg/ml),
and 5x10-SM
gentamicin (i0 zg/ml)
2-mercaptoethanol.
10% fetal calf serum,
c) Subculturing of T cell lines
After 3 days, T cell lines were subcultured by
plating them at i0 cells/well in round bottom 96-well
plates (Costar) along with recombinant IL-2 10 u/cc
(Amgen, Thousand Oaks, California), 2x105 irradiated SJL/J
splenocytes and porcine MBP or PPD. These subcloning
cultures were fed twice a week with IL-2, and once every
other week with irradiated SJL/J splenocytes and porcine
MBP or PPD. As T cells became morphologically apparent in
the cultures, they were expanded into 24 well plates as
needed. In addition, the heterogeneous lymph node-derived
cells were grown as an IL-2 dependent T cell line using
the approach outlined above without the initial plating at
i0 cells per well.
d) Proliferation assay
Antigen reactivity of the MBP-specific IL-2
dependent T cell lines (8BO, F128, All, D47) and other
antigen-specific IL-2 dependent T cell lines (OVA-0-15,
BIOS-6-20, PPD-13-28, PPD-12 and 9PPD) were assessed via
3H-thymidine incorporation proliferation assays. In these
assays, 3xi04 line cells were added to 3xi05 irradiated
SJL/J splenocytes in 0.2 ml volume of RPMI 1640 with 10%
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fetal calf serum in the absence of IL-2 and in the
presence or absence of optimal concentrations of antigens
(Porcine myelin basic protein, PMBP Purified protein
derivative, PPD and Ovalbumin, OVA). These cultures were
maintained at 37 in 10% CO2 for 48 hours. 2 DCi of
3H-thymidine were then added, and the amount of
3H-thymidine incorporated into cellular DNA assayed 24
hours later with the aid of semiautomated cell harvested
and beta-scintilography. The results were expressed as
arithmetic means of c.p.m, from triplicate cultures +
standard deviation.
II. Generation of T-anti T Cell Lines
The T-anti T cell lines or responder T cell lines
were generated from the spleen of an SJL/J mouse immunized
7 days earlier with the irradiated (6,000 rad; 137Cs) EAE-
inducing line-8BO (0.9cc i.p. at 95.8x106 cells/cc)
Seven days post-immunization, the spleen was removed and
cultured at 1.5x106 cells/well with the irradiated (7,500
rad; 137Cs) EAE-inducing line 8BO at 1.5xi06 cells/well in
RPMI 1640 supplemented with 10% fetal calf serum and
2-mercaptoethanol (complete media, CM) in a 24 well tray
(Costar) After 7 days of primary culture, the viable
cells were isolated on Ficoll-Hypaque and cloned in IL-2
i0 u/cc) in a 96 well round tray (Costar) at 50
cells/well.
irradiated
In addition,
8BO line (5x104
these cultures received the
cells/well for the first
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carried out for previous experiment. Lines generated by
this experiment were termed line B1 to B30.
a) Proliferation assays
1 Proliferation assay in response to two
different concentrations of EAE-inducing line (8BO)
In the preliminary screen for relevant lines,
antigen specificity was examined in a 72 hour proliferation
assay. 3x104 cells/well of responder T cell lines were
plated in CM with 3x105 cells/well autologous irradiated
(2,500 rad; 137Cs) SJL/J splenocytes and with ixl05
cells/well
rad; 137Cs)
or 5xi05 cells/well of the irradiated (7,500
EAE-inducing line (8BO) in 96 well flat-
bottomed tray (Costar) at 0.2 ml final volume. In
addition, irradiated splenocytes and the irradiated 8BO
line were tested
concentrations of
alone as
cells for
a control using two different
8BO (Ix105 cells/well and
5x105 cells/well) After 48
with 0.2 zCi 3H-thymidine and
hours later. Incorporation of
hours, culture were pulsed
cells were harvested 24
3H-thymidine were measured
by liquid scintillation spectroscopy. The results were
expressed as arithmetic means of counts per minute
(c.p.m.) from triplicate cultures + standard deviations.
2) Proliferation assay in the absence of antigen
presenting cell (APC)
Antigen specificity was examined in the
absence of antigen presenting cells (APC) in a 72 hour
proliferation assay. 3x104 cells/well of responder lines,
3O
stimulation cycle and ixl05 cells/well for further
stimulation cycles) and
(2,500 rad; 137Cs) at
autologous irradiated
3x105 cells/ well as
splenocytes
a source of
antigen presenting cells. The wells demonstrating
positive growth were
(Costar) with irradiated
autologous irradiated
transferred to a 48 well plate
8BO line (0.5xi06 cells/well) and
splenocytes (1.5xi06 cells/well) in
the presence of interleukin-2 (i0 u/cc). Following further
culture, the lines with positive growth were transferred
to a 24 well plate (Costar) with the irradiated 8BO line
ixl06
(3x106
cells/well) and autologous irradiated splenocytes
cells/well in the presence interleukin-2
(i0 u/cc). All 96, 48 and 24 well plates, were fed every
other week with the irradiated 8BO line and autologous
irradiated SJL/J splenocytes in the presence of
interleukin-2 (I0 u/cc) alone. In addition, these cells
were fed twice a week with interleukin-2 (I0 u/cc). Lines
generated by this experiment were termed line A1 to A30.
7dditional responder T cell lines were generated in a
similar manner, except that, 7
spleen cells from immunized an mouse
cells with the irradiated 8BO
days post-immunization,
were cultured (20x106
line (4xi06 cells) in a
flask (I0 cc final volume) for 3 days. After 3 days, the
viable cells were isolated on Ficoll-Hypaque and cultured
with interleukin-2 (i0 u/cc) for 4 days. After 4 days,
the viable cells were cloned using the same procedure
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were plated in CM alone or with
irradiated (6,000 tad; 137Cs)
5x105
8BO or
cells/well of the
with lines of
different antigen specificities (PPD 13-28 or 9PPD), but
without autologous irradiated splenocytes, in 96
bottomed plate (Costar) at 0.2 ml total volume.
well flat
Cultures
were pulsed and harvested as previously described.
3) Proliferation assay in response to EAE-
inducing line (8BO) and lines with different antigen
specificities (PPD-13-28)
In the preliminary screen for relevant lines,
antigen specificity was examined in a 72 hour
proliferation assay. 3x104 cells/well of responder T cell
lines were plated in CM with 3x105 cells/well of
autologous irradiated SJL/J splenocytes and 5xl 05
cells/well of the irradiated 8BO line. In addition each
line were also tested for stimulation with autologous
irradiated splenocytes (3x105 cells/well) alone or with an
irradiated line (6,000 rad; 137Cs) with a different
antigen specificity (PPD-13-28) at 5x105 cell/well.
Irradiated autologous splenocytes with irradiated 8BO line
or with the PPD-13-28 line were used as controls. Each
group was tested in triplicates in a 96-well-flat-bottomed-
tray at 0.2 ml final volume. Cultures were pulsed and
harvested as previously described.
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4 Antigen specificity of the in vitro
proliferation of the responder line A4 in mouse serum
This assay was carried out the same way as
assay a.3. except that, line A4 was used and plated with
0.5% of mouse serum in the absence of 10% fetal calf
serum.
5) Proliferation assay of the responder T cell
lines in 0.5% of mouse serum
This assay was carried out the same way as
assay a.3., except that, the responder T cell lines were
plated with 0.5% mouse serum, and tested using an
irradiated line with a different antigen specificity
(PPD-6-20).
6) Proliferation assay in response to 8BO line
and to lines with different antigen specificities in 0.5%
of mouse serum
Antigen specificity was examined in a 72 hour
proliferation assay. 3xi04 cells/well of line A4 was
plated in CM with 3x105 cells/well of autologous
irradiated SJL/J splenocytes and 5x105 cells/well of the
irradiated 8BO line alone or with PMBP at i0 zg/cc. In
addition, line A4 was also tested with autologous
irradiated splenocyte at 3x105 cells/well alone or with
PMBP (i0 Dg/cc) and with irradiated lines/clones (6,000
rad; 137Cs) with different antigen specificities (PPD-12,
All, 8B0-57, F128, OVA-015 and D47) at 5x105 cells/well.
Irradiated splenocytes with irradiated 8BO line or with an
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irradiated irrelevant clone/line (PPD-12 All 8B0-57
F128; OVA-015 and D47) were used as controls. Each group
were tested in triplicates in a 96-well-flat-bottomed-trays
at 0.2 ml final volume. Cultures were pulsed and harvested
as previously described.
7 Proliferation assay in response to the 8BO
line and to lines/clones with different antigen
specificities in 0.5% of mouse serum
Antigen
proliferation assay.
specificity was examined in a 72 hour
3x104 cells/well of line A4 was
plated in RPMI 1640 supplemented with 0.5% mouse serum and
2-mercaptoethanol with 3x105 cells/well of autologous
irradiated SJL/J splenocytes and 5x105 cells/well of the
irradiated 8BO line alone or together with PMBP at
i0 Dg/cc. In addition, line A4 was also tested alone or
with autologous irradiated splenocytes at 3xi05 cells/well
alone or with PMBP (I0 ug/cc) and with the irradiated
lines/clones with different antigen specificities with
their antigens (PPD clone, PPD clone+PPD, OVA clone, OVA
clone+OVA, DI0 clone, F128 line, F128 line+PMBP antigen)
at 5xl 0 5 cells/well. Irradiated splenocytes with
irradiated 8BO line or with irradiated non-PMBP-specific
clones/lines (PPD clone, OVA clone, DI0 clone and F128
line) were used as controls. In order to test if line A4
needed antigen presenting cells to respond to 8BO line,
all combinations were tested in absence of APC. Each
group was tested in triplicates in a 96-well-flat-bottomed
35
trays at 0.2 ml final volume. Cultures were pulsed and
harvested as previously described.
III. In Vivo Effects of the Responder T Cell Line A4 and
the Stimulator Cell Line 8BO
To assess the ability of responder T cell line (A4)
and the stimulator cell line 8BO to induce or suppress EAE
in SJL/J mice, a total of 4 animals received sublethal
irradiation (350 rad;137Cs) Each animal was injected
intraperitoneally as follows- animal #i received 0.5 cc
of line A4 at 18x106 total cells and 0.5 cc of the 8BO
line at 15x106 total cells; animal #2 received 0.5 cc of
the 8BO line at 15x106 total cells and 0.5 cc of PBS;
animal #3 received 0.5 cc of line A4 at 18x106 total cells
and 0.5 cc of PBS; animal #4 received 0.5 cc of a clone
with a different antigen specificity (9PPD) at 18x106
total cells and 0.5 cc of EAE-inducing line (8BO) at
15xi06 total cells.
Mice were observed at least through day 10 for
clinical signs. The clinical status of the mice was
graded on a 0 to 5 scale of increasing severity- 0, no
abnormality 1, tail weakness 2, tail weakness with
moderate hind limb weakness; 3, hind leg paralysis and
eventually mild forelimb weakness 4, quadriplegia or
premoribund state; 5, death of animal in acute EAE.
A second similar experiment was carried out, except
that animal #I received 0.5 cc of line A4 at 25xi06 total
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cells, line 8B0 at 10x106 total cells, PMBP at 20 zg and
PBS; animal #2 received 8BO line at 10x106 total cells,
PMBP at 20 zg and PBS; animal #3 received a PPD-speciic
clone (9PPD) at 25xi06 total cells, 8BO at 10xl06 total
cells, PMBP at 20 zg and PBS; animal #4 received 8BO line
at 10x106 total cells and PBS.
Mice were observed and graded as previously
described.
IV. Surface Phenotype of the Responder Line
Surface marker characterization was carried out to
phenotype the responder line A4. Cells were resuspended
in a 1 cc of 10% Sodium Azide (SA). The pellet was
resuspended and washed 3x with PBS/SA. After the last
wash, cells were resuspended in 0.8 cc of PBS/SA. An
aliquot of 0.i cc was taken and added into 3 Eppendorf
tubes. To each tube was added 0.i cc of: a 1:40 dilution
of a monoclonal rat anti-L3T4 or a i" 50 dilution of
anti-Lyt2. In the third tube no antibody was added (PBS
as a control). The cells were incubated for 15 to 30 min
at 4C. After incubation, 3 washes were performed by
adding 1 ml of PBS/SA. A second antibody (Goat anti-rat
antibody conjugated to FITC) was added to all 3 tubes and
incubated for 30 min at 4C. The cells were washed 2
times with PBS/SA and fixed, then 0.i ml of PBS/SA was
added to 0.I ml of fixative after diluting 1.5M NaCl I-i0
with 10% formalin.
RESULTS
Of the PMBP responsive lines tested to be the
"stimulating" line in the generation of "suppressor or
respoder" T cell lines, line 8BO was selected. This line
was selected based on the criterion of responsiveness to
MBP using an in vitro proliferation assay and the in vivo
mediation of EAE. To test for antigen reactivity of the
EAE inducing line and control lines, an in vitro
proliferation assay (shown in Table I) was used. Cells
from individual lines were plated with APC in the presence
or absence of their respective antigens.
The results in Table I indicated that all T
lymphocyte lines proliferated strongly and specifically
only with their specific antigens. However, in the
absence of their antigens, all T lymphocyte lines had a
significant lower response. The proliferative response of
T lymphocyte lines towards unrelated antigens was
negative, but not shown.
Of the PMBP responsive lines (8BO, F128, D47, All)
tested in vivo, only 8BO line was consistently able to
mediate EAE in vivo (in 100% of SJL/J mice, data not
shown)
38
37
The cells in each tube were further processed for an
analys’is on the fluorescence-activated cell sorter (FACS)
and by using a fluorescence microscope.
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I. In Vitro Studies
Tables II to IX show the proliferative response of T
cell lines generated from spleens of SJL/J mice that had
been immunized with the irradiated MBP-specific T cell
line (8BO) These responder lines were grown in vitro
with the irradiated stimulator T cell line (8BO) and
antigen presenting cell (APC) in the presence of IL-2
containing medium as described in Materials and Methods.
The proliferative assays shown (Tables II to IX)
represent typical experiments testing the response and
specificity of the responder lines towards line 8BO. Some
responder lines were stimulated and others suppressed by
8BO. These responses of either stimulation or suppression
were generally greater when higher concentration of 8BO
were used. Tables II and III show typical responses of
responder lines AI, A7, AI2, B2, B3. These assays were
all performed in the presence of fetal calf serum.
In Table IV, we examined the requirement for
irradiated spleen (as APC) in the responses noted. As can
be seen, a number of responder lines were capable of
responding to 8BO (eg: line A3 and B3 or to a
PPD-specific lines PPD 13-28 and 9-PPD (eg- line A1 AI2
and B3) in the absence of APC. Other lines however, were
totally unresponsive to either 8BO or 9-PPD in the absence
of APC. Of note was the finding that the high background
counts seen in Tables II and III were not seen in the
4O
absence of APC. Thus, APC was not necessarily important
for some of T-T cells interactions noted above.
In the next experiment, shown in Table V, T cell
lines were stimulated with either an irradiated
EAE-inducing line or an irradiated PPD-specific line at
5xi05 cells/well. Once again, it can be seen that certain
responder lines were suppressed by either 8BO or PPD 13-28
(eg: A9, B3, B9), while others were suppressed only by 8BO
(eg- AI). In contrast, some lines were stimulated rather
specifically by 8BO (eg- A4, AI2)
Because of the continued high background counts seen
in the presence of APC, it appeared that all the responder
lines were at least partially responding in either an
autologous mixed lymphocyte reaction (AMLR) or responding
to antigenic determinants in fetal calf serum.
To attempt to understand and eliminate the high
background counts, all subsequent tests were performed in
the absence of fetal calf serum and, instead, in the
presence of 0.5% autologous mouse serum. As can be seen
in Table VI, with A4, the change to mouse serum greatly
decreased the background counts, suggesting that these
proliferation responses were in response to fetal calf
serum determinants. As can also be seen in Table VI, the
responses of A4 towards 8BO and PPD-13-28 persisted
despite the absence of fetal calf serum.
In Table Vll, a panel of responder lines have been
tested in the presence of 0.5% mouse serum and in the
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absence of fetal calf serum. As can be seen, a number of
responder lines now demonstrated no significant
proliferative response to either 8BO or PPD-6-20 (lines
AI7, BII, BI6, B21) while other lines showed responses to
both 8BO and PPD-6-20 (lines AI, A4, AI2, B3).
In Table VIII, line A4 has been singled out for
further study, and its responses to a number of different
irradiated stimulator clones is shown. As can be seen in
Table Vlll, A4 responded well to 8BO, PPD-12, A-II, 8B0-57
(a MBP-specific clone of 8BO) OVA-0.15, D47, but
responded poorly to line F128. It should also be noted
that in this experiment line A4 itself, showed a response
to PMBP as did the irradiated line 8BO) Of most
interest, however, was the finding that the response of A4
to 8BO was significantly decreased in the presence of
PMBP.
This surprising finding was investigated further in
experiments in which A4 was stimulated with irradiated
PPD-specific and ovalbumin (OVA)-specific clones, in the
presence or absence of PPD or ovalbumin, respectively. As
can be seen in Table IX, A4 responded to the PPD clone,
but in the presence of PPD this response increased. This
was in contrast to the response to 8BO which again
decreased in the presence of PMBP. A4 responded to the
OVA-specific clone, and in the presence of ovalbumin this
response also decreased but to a much lesser degree than
with 8BO and PMBP. As can also be seen in Table IX, A4
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again did not respond to the MBP-specific line F128, but
the baseline response to F128 nevertheless decreased by
aproximately 50% in the presence of PMBP. A4 itself was
again seen to respond to PMBP. Thus, unlike the situation
with A4 and 8BO and A4 and F128, PMBP itself did not
suppress the proliferation of A4 in the presence of APC
alone. Finally, as can be seen in Table IX, A4 did not
respond to DI0, which is an allogeneic clone specific for
ovalbumin and derived from an AKR mouse (a generous gift
of Dr. Charles Janeway and Dr. K. Bottomly, Yale
University)
II. In Vivo Studies
The in vivo effects of the anti-8BO cell line A4 on
the EAE-inducing line 8BO was next studied (Tables X and
Xl)
Both lines were injected intraperitoneally into a
naive, irradiated (350 rad) SJL/J mouse; A4 at 18x106
cells/mouse and 8BO at 15xi06 cells/mouse. We found that
line A4 did not protect the mice from 8BO mediated EAE.
As shown in Table X, when A4 and 8BO were inj ected
together, the first signs of EAE developed at day 7, and
within I0 days the mouse was dead. 8BO injected alone
into a mouse led to the same clinical outcome except that
the disease onset was at day 6. However, when the control
line 9PPD was injected with 8BO, only mild clinical signs
were observed (maximal severity-l) from day 6 through day
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I0. We have noted such a modulation of signs of EAE with
PPD lines previously, but only inconsistently. Line A4
inject.ed alone failed to mediate any signs of EAE.
In Table XI, we asked whether an increase in the
amount of line A4 injected or the injection along with
PMBP could affect the mediation of EAE described above.
The latter question was based on our in vitro observation
that PMBP could suppress A4’s response to PMBP-specific
lines. We postulated that the addition of PMBP might lead
to the secretion of suppressor factors by A4. The
simultaneous injection of PMBP did not seem to modify the
clinical signs of the disease in any cases. However,
injecting line A4, at 25xi06 cells per mouse along with
8BO at 10x106 cells per mouse together with PMBP seemed to
accelerate the disease onset (3 days earlier than the
previous experiment) No attempt was made to test A4
alone or with PMBP in these experiments.
III. Analysis of Surface Membrane Markers of the Responder
Line
Surface marker characterization was carried out to
phenotype the responder line A4. Treatment of line A4
cells with rat antibodies to the determinat Lyt2+ and with
a monoclonal antibody to L3T4 followed by a secondary
antibody fluorescein conjugated-goat anti-rat antibody)
indicated that the A4 line cells did not express Lyt2+ on
their surface, but did express L3T4. The control cells,
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which did not receive any primary antibody was negative.
The results of fluorescence-activated cell sorter (FACS)
analyses are shown in Figures i, 2, and 3.
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Table I. In vitro proliferation assay (c.p.m. 3H-TdR) of the EAE-
inducing line (8BO), and control lines.
Responder Stimulator cel s
T cel s APC
APC APC APC
+ +
PMBP PPD OVA
8BO 977+-424 221,263+-11,922
F128 1,013_+293 203,624_+38,920
OVA O. 15 1,544+977 220,025_+23,850
BIOS-6-20 977+178 81,260_+6,093
A-11 524_+193 59,316_+11,890
PPD-13-28 310+124 19,352+_3,406
D47 1,011+505 70,424+23,663
PPD-12 293+ 94 275.127+76.069
9 PPD 1.912+182 230.791+_36.308
To tes% for antigen reactivity, responder T cell lines were plated in
RPMI 1640 supplemented with 10% fetal calf serum and 2-mercaptoethanol
at 3x104 cells/well with 3x105 cells/well autologous irradiated
splenocytes (2,500 rad; 137Cs) in the presence or absence of optimal
concentrations of antigens (porcine myelin basic protein PMBP,
purified protein derivative of tuberculin PPD and ovalbumin OVA) in
96-well-flat-bottomed trays (Costar) at 0.2 ml final volume.
46
Table I (cont’d)
After 48 h, cultures were pulsed with 2Ci 3H-thymidine and cells were
harvested 24 h later. Incorporation of 3H-thymidine was measured by
liquid, scintillation spectroscopy. The results are expressed as
arithmetic means of c.p.m. from triplicate cultures + standard
deviation.
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Table II. In vitro proliferation assay (c.p.m. 3H-TdR) in response to
two different concentrations of EAE-inducing line (8BO).
Responder Stimulator cel Is
T cell APC APC + 8BO APC + 8BO
(105 cel Is/well) (5x105 cell s/well)
A1 51,682+_ 7,223 81,209+_ 2,340 112,477-+2,091
A7 126,900+_ 9,618 108,239_+21,619 45,928_+2,162
A12 42,927_+16,723 72,957_+ 7,414 69,110+-8,942
833_+ 278 1,263-+ 961
To test for antigen specificity, lines A1, A7 and A12 were plated in
RPMI 1640 supplemented with
at 3xi04 cells/well, with autologous irradiated (2,500 rad;
splenocytes 3x105 cells/well and Ix105 cells/well or 5x105
the irradiated (7,500 rad; 137Cs) EAE-inducing line (8BO)
10% fetal calf serum and 2-mercaptoethanol
137Cs) SJL/J
cells/well of
n 96-wel
flat-bottomed trays (Costar) at O.2ml final volume. After 48 h, cultures
were pulsed with O.2NCi 3H thymidine and cells were harvested 24 h
later. Incorporation of 3H-Lhymi dine was measured by liquid
scintillation spectroscopy. The results are expressed as arithmetic
means of c.p.m, from triplicate cultures + standard deviation.
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Table III. In vitro proliferation assay (c.p.m.
two different 8B0 concentrations.
3H-TdR) in response to
Responder Stimulator cells
T cell APC APC + 8B0 APC + 8B0
(105 cel Is/well) (5x105 cells/wel I)
B2 211,669+ 8,841 190,276+25,798
B3 65,492+20,085 104,614+ 5,713
126,087_+13,502
121,490_+17,753
To test for antigen specificity, lines B2 and B3 were plated in RPMI
1640 supplemented with 10% fetal calf serum and 2-mercaptoethanol at
3x104 cells/well with 3x105 cells/well autologous irradiated (2,500 rad;
137Cs) SJL/J splenocytes and Ix105 cells/well or 5x105 cells/well of the
irradiated (6,000 rad; 137Cs) EAE-inducing line (8BO) in 96-well-flat-
bottomed trays (Costar) at 0.2 ml final volume. After 48 h, cultures
were pulsed with 2NCi 3H thymidine and cells were harvested 24 h later.
Incorporation of 3H-thymidine was measured by liquid scintillation
spectroscopy. The results are expressed as arithmetic means of c.p.m.
from triplicate cultures + standard deviation.
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Table IV. In vitro proliferation assay (c.p.m.
APC.
3H-TdR) in the absence of
Responder Stimulator cel s
T cell Media 8BO PPD-13.28 9-PPD
A1 90+ 34 173+ 59 2,532+368
A3 112+ 7 918+534 686+147
A8 103+ 37 315+241 402+212
A12 269+ 374+ 95 1,073+134
B2 445+187 332+166 538+ 97
B3 263_+130 1,361+_199 2,903_+259
B7 411+209 162+ 54 578+ 43
104+ 32 239+ 75
To test for antigen specificity, lines A1, A3, A8, A12, B2, B3 and B7
were plated in RPMI
mercaptoethanol at
irradiated (6000 rad;
of
1640 supplemented with 10% fetal calf serum and 2-
3x104 cells/well with 5x105 cells/well of the
137Cs) EAE-inducing line (8BO) or 5x105 cells/well
irradiated (6,000 rad; 137Cs) lines with a different antigen
specificities (PPD-13-28 or 9PPD) but without autologous irradiated
splenocytes, in 96-well-flat-bottomed trays (Costar) at 0.2 ml final
volume. After 48 h, cultures were pulsed with 2Ci 3H thymidine and
cells were harvested 24 h later. Incorporation of 3H-thymidine was
measured by liquid scintillation spectroscopy. The results are expressed
as arithmetic means of c.p.m, from triplicate cultures +_ standard
deviation.
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Table V. In vitro proliferation assay (c.p.m. 3H-TdR) in response to
EAE-inducing line (8BO) and a line with different antigen
specificity (PPD-13-28).
Responder Stimulator cel Is
T cell APC APC + 8BO APC + PPD-13-28
A1 154,030+ 3,987 112,556+24,980 161,316+11,374
A4 99,679_+34,286 150,93 I--- 4,036 103,360__. 0,90
A9 134,361_.+17,749 57,719_+ 7,458 51,264--.12,740
A12 98,467_+ 5,468 149,322_-.11,271 118,409_+ 6,301
B2 256,258+22,108 256,902+13,992 151,761+30,144
B3 168,011+35,257 22,236+ 5,604 33,326+ 0,64
B9 161,315_+18,326 25,910_+ 9,125 16,805_+ 1,755
947+_. 338 1,400__. 581
To test for antigen specificity, T cell lines were plated in RPMI 1640
supplemented with 10% fetal calf serum and 2-mercaptoethanol at 3xi04
cells/well with 3x105 cells/well autologous irradiated (2,500 rad 137
Cs) SJL/J splenocytes and 5xi05 cells/well of the irradiated (6,000 rad
137Cs) EAE-inducing (8BO) or 5x105 cells/well of the irradiated (6,000
rad; 137 Cs) line with a PPD-specific line (PPD-13-28) in 96-well-flat-
bottomed trays (Costar) at 0.2 ml final volume. After 48 h, cultures
were pulsed with 2NCi 3H thymidine and cells were harvested 24 h later.
Incorporation of 3H-thymidine was measured by liquid scintillation
spectroscopy. The results are expressed as arithmetic means of c.p.m.
from triplicate cultures + standard deviation.
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Table VI. Antigen specificity of the in vitro proliferation (c.p.m.
TdR) of the responder A4 line in mouse serum.
Responder Stimulator cell
T cell APC APC + 8BO APC + PPD-13-28
A4 1,525+203 6,582+1,838 32,696+5,017
417 382
To
supplemented with 0.5% mouse
cells/well with 3x105 cells/well
Cs) SJL/J splenocytes and 5x105
rad; 137 Cs) EAE-inducing line
test for antigen specificity, line A4 was plated in RPMI 1640
serum and 2-mercaptoethanol at 3xi04
137autologous irradiated (2,500 rad;
cells/well of the irradiated (6,000
(8BO) or 5x105 cells/well of the
irradiated (6,000 rad; 137 Cs) PPD-specific line (PPD-13-28) in 96-well-
flat-bottomed trays (Costar) at 0.2 ml final volume.
cultures were pulsed with 2NCi 3H thymidine and cells were
h later. Incorporation of 3H-thymidine was measured
After 48 h,
harvested 24
by liquid
scintillation spectroscopy. The results are expressed as arithmetic
means of c.p.m, from triplicate cultures _+ standard deviation.
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Table VII. Antigen specificity of the in vitro proliferation (c.p.m. 3H-
TdR) response of T cell lines in mouse serum.
Responder Stimulator cel Is
T cell APC APC + 8BO APC + PPD-6-20
A1 475+ 88 6,063+ 254 8,292+ I, 586
A4 1,847_+I,082 33,457_+ 1,180 46,384_+ 9,966
A12 631+ 305 9,119+ 5,544 10,564+ 1,831
A17 953+ 143 I, 462+ 250 1,929+ 202
B3 21,530+3,799 92,957+13,475 101,361+23,217
Bll 1,581+ 47 2,968+ 3,003 1,186+ 381
B16 931+ 221 826+ 146 1,189+ 170
B21 848_+ 158 1,039-+ 393 1,760-+ 389
313_+ 63 363-+ I0
To test for antigen specificity, T cell lines were plated in RPMI 1640
supplemented with 0.5% mouse serum and 2-mercaptoethanol at 3x104
cells/well with 3x105 cells/well autologous irradiated (2,500 rad; 137
Cs) SJL/J splenocytes and 5xi05 cells/well of the irradiated (6,000 rad;
137 Cs) EAE-inducing line (8BO) or 5x105 cells/well of irradiated (6,000
rad; 137 Cs) PPD-specific line (PPD-6-20) in 96-well-flat-bottomed trays
(Costar) at 0.2 ml final volume. After 48 h, cultures were pulsed with
2Ci 3H thymidine and cells were harvested 24 h later. Incorporation of
3H-thymidine was measured by liquid scintillation spectroscopy. The
results are expressed as arithmetic means of c.p.m, from triplicate
cultures + standard deviation.
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Table VIII. In vitro proliferation (c.p.m. 3H-TdR) in response to EAE-
inducing line (8BO) and to lines with different antigen
specificity in mouse serum.
Responder T cell (A4) and
Stimulator cel s Stimulator cells alone
APC 15,131+_ 4,644
APC+8BO 37,679+ 3,315 445+201
APC+8BO+PMB P 4,749+ 730 3,023+245
APC+PPD-12 38,898+15,257 261+ 54
APC+A-11 42,053+ 6,361 847+679
APC+8BO-57 45,839+16,381 228+ 70
APC+F128 19,213+_ 2,049 350_+109
APC+OVA-0.15 41,691+16,805 148+ 33
APC+D47 37,978+ 4,278 596+174
APC+PMBP 26,858+_11,787
To test for antigen specificity, line A4 was plated in RPMI 1640
supplemented with 0.5% mouse serum and 2-mercaptoethanol at 3xi04
cells/well with 3x105 cells/well autologous irradiated (2,500 rad; 137
Cs) SJL/J splenocytes and 5x105 cells/well of the irradiated (6,000 rad;
137 Cs) EAE-inducing line (8BO) or 5x105 cells/well of irradiated (6,000
rad; 137 Cs) lines with different antigen specificities (PPD-12; A-11,
8B0-57, Fl18; OVA-15 and D47) with or without PMBP at lOg/ml cc in 96-
well-flat-bottomed trays (Costar) at 0.2 ml final volume. After 48 h,
cultures were pulsed with 2NCi 3H thymidine and cells were harvested 24
h later. Incorporation of 3H-thymidine was measured by liquid
scintillation spectroscopy. The results are expressed as arithmetic
means of c.p.m, from triplicate cultures + standard deviation.
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Table IX. In vitro proliferation (c.p.m. 3H-TdR) of A4 in
response to EAE-inducing line (8BO) and to lines with
different antigen specificities in mouse serum.
Responder T cell (A4) and
Stimulator cel s Stimulator cells alone
Media 521+ 281
APC 11,055+1,347
PMBP + APC 16,230_+9,604
APC+PPD clone 23,034_+8,349 2,222+203
APC+PPD clone + PPD 38,300+_6,313
APC+OVA c one 22,693+3,909 278+ 3
APC+OVA clone + OVA 16,557_+1,622
APC + 8BO 16,636+3,259 333+206
APC+8BO+PMBP 6,779_+4,248
APC+DIO 12,051+2,707 655+194
APC+F128 10,259+ 657 403+151
APC+F128 + PMBP 5,218+_ 34
8BO (no APC) 301+ 45
cont’d on next page
Table IX (cont’d)
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To test for antigen specificity, line A4 was plated in RPMI 1640
supplemented with 0.5% mouse serum and 2-mercaptoethanol at 3x104
cells/well with 3xi05 cells/well autologous irradiated (2,500 rad; 137
Cs) SJL/J splenocytes and 5x105 cells/well of the irradiated (6,000 rad;
137 Cs) EAE-inducing line (8BO) or 5xi05 cells/well of irradiated (6,000
rad; 137 Cs) lines with different antigen specificities (PPD, OVA, DIO,
F128) with or without (PMBP; PPD; OVA) at 10g I cc in 96-well-flat-
bottomed trays (Costar) at 0.2 ml final volume. After 48 h, cultures
were pulsed with 2Ci 3H thymidine and cells were harvested 24 h later.
Incorporation of 3H-thymidine was measured by liquid scintillation
spectroscopy. The results are expressed as arithmetic means of c.p.m.
from triplicate cultures + standard deviation.
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Table X. Ability of responder T cell
in SJL/J mice.
line A4 to modify 8BO-induced EAE
Day of Onset (n) of mice
Final Severity of
clinical disease
6 7 8 9 10 0 1 2 3 4 5
A4+8BO + I +
8BO alone + I +
A4 al one 1 +
9PPD+8BO + 1 +
To assess the ability of line A4 to modify 8BO-induced EAE in naive
mice, 4 animals received sublethal irradiation (350 rad; 137Cs) and were
injected i.p. as follows" animal #I received A4 line at 18x106 cells and
the EAE-inducing line (8BO) at 15x106 cells; animal #2 received EAE-
inducing line (8BO) alone; animal #3 received A4 line at 18xi06 cells
alone and animal #4 a line with different antigen specificity (9PPD) at
18x106 cells and EAE-inducing line (8BO) at 15x106 cells. Mice were
observed at least through day 10 for clinical signs. The status of the
mice were graded on a 0 to 5 scale of increasing severity" O, no
abnormality; 1, tail weakness; 2, a floppy tail weakness with moderate
hind limb weakness; 3, hind leg paralysis and eventually mild forelimb
weakness; 4, quadriplegia or premoribund state; 5, death.
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Table XI. Ability of the responder T cell line A4 to modify 8BO-induced
EAE in SJL/J mice in the presence of PMBP
Day of Onset (n) of mice
Final severity
of clinical disease
4 7 9 10 0 1 2 3 4 5
A4+8BO+PMBP + 1 +
8BO+PMBP + 1 +
9PPD+8BO+PMBP 1 +
8BO al one + 1 +
To assess the ability of line A4 to modify 8BO-induced EAE in a naive
mouse, 4 animals received sublethal irradiation (350 rad; 137Cs) and
were injected i.p. as follows" animal #I received A4 line at 25x106
cells, the EAE-inducing line (8BO) at 10xi06 cells and porcine myelin
basic protein (PMBP) at 20 g; animal #2 received EAE-inducing line
(SBO) at 10xi06 cells and porcine myelin basic protein (PMBP) at 20 Ng;
animal #3 received purified protein derivative line (9PPD) at 25x106
cells, EAE-inducing line (8BO) at 10x106 cells and porcine myelin basic
protein (PMBP) at 20 g; animal #4 received EAE-inducing line (8BO)
alone at I0xi06 cells. Mice were observed at least through day 10 for
clinical signs. The clinical status of the mice were graded on a 0 to 5
scale of increasing severity (see previous table X).
58
350
10o 102 10.
Intensity Fluorescence
Fig. 1 Surface phenotype of the
A4 was incubated with a
antibody and then with
antibodies. The amount of
responder line A4. Line
monoclonal anti-Lyt2 rat
FITC-conj ugated anti-rat
biding was assayed using
FACS analysis.
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Fig. 2 Surface phenotype of the responder line A4.
A4 was incubated with a monoconal anti-L3T4
antybody and then with FITC-conj ugated
anti-rat antibodies. The amount o f binding
Line
rat
goat
was
assayed using FACS analysis.
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Intensity Fluorescence
Fig.3 Surface phenotype of the responder line A4. Line
A4 was incubated with PBS and then with FITC-
conjugated goat anti-rat antibodies. The amount
of binding was assayed using FACS analysis.
DISCUSSION
In these studies, we have attempted to isolate T cell
lines that were reactive and specific for EAE-mediating T
cell lines. We postulated that we could generate T cell
lines that would be specific for the antigen receptors on
EAE mediating lines or clones. What: we in fact have been
able to accomplish is the generation of T cell lines that
appear to be reactive to most T cell lines or clones.
We initially noted that our responder lines were
stimulated by irradiated splenocytes alone (Table II, III
and V). This suggested that the lines might be responding
in an autologous mixed lymphocyte reaction (AMLR) In the
AMLR, T cells recognize and are stimulated by self Ia
displayed by the irradiated autologous antigen presenting
cells (APC) The other possibility, however, was that
fetal calf serum proteins were acting as antigens and
stimulating the responding T cells lines. In other words,
either Ia antigens alone on the APC were stimulating our
responder T cell lines or fetal calf serum antigens
together with Ia antigens were stimulating the responder T
cell lines. It is well established that interactions
between soluble protein-reactive T cells and either the
soluble antigen alone or syngeneic APC alone is not
sufficient to induce proliferation (Janeway et al. 1976)
However, studies of the AMLR have indicated that
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autologous APC can at times, in the absence of added
antigen, induce proliferation through their Ia antigens
alone among soluble protein reactive T cell (Hausman et
al., 1981) In fact, Hausman et al. (1980) and Raff et
al. (1980) reported that the AMLR actually represents
proliferation among two distinct population of T cells in
response to signals from distinct stimulator cells. One
population of T cells is activated by stimulators present
in autologous B cell- enriched, macrophage-depleted cells,
whereas another is induced to proliferate by signals from
a subpopulation of autologous macrophages.
To distinguish between the AMLR and a fetal calf
serum response, we tested our lines in the absence of
fetal calf serum, using autologous mouse serum instead.
We initially found that the line A4 showed no AMLR when
assayed in mouse serum. However, in later assays, even in
mouse serum, the response of A4 to APCs alone was again
found to be increasing. This suggests that the response
of A4 to APCs alone initially represented a response to
fetal calf serum determinants, and perhaps later, a true
AMLR.
In the present studies we have found that the
reaction between some of the responder T cell lines and
stimulator T cell lines did not require antigen presenting
cells (Table IV). This is consistent with the studies of
Lamb and Feldman (1982), in which they generated human
regulatory T cell clones against a T helper cell which
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recognizes influenza A matrix protein in the absence of
APC. In addition, this finding is consistent with the
reports of Damle et al. (1983 and 1984); Mohagheghpour et
al. (1984) and Mohagheghpour et al. (1986) who have
described (in humans) a form of T suppressor cell which is
activated by direct interaction with the antigen receptors
on antigen- primed inducer T cells.
In examining the response and specificity of our
responder lines, we found that our responder T cell lines
appeared to be stimulated by determinants expressed on
both the EAE-mediating line and on unrelated lymphoblasts.
Suzuki et al. (1986) have reported the only studies of
murine T cells reactive to other T cells. They have shown
that resting murine T cells can be found to proliferate in
response to T cell blasts. These authors did not generate
long term lines from their responding resting T cells.
Although they found that this response was not dependent
on the presence of APC, they nevertheless found that their
T-T responses could be inhibited by anti-Ia antibodies.
These authors could not explain their surprising findings
that APC were not necessary, that murine T cells do not
express Ia antigens and yet, anti-Ia antibodies could
inhibit their responses. As noted above, we have found
that our T-T responses occur both in the presence and
absence of APC. Furthermore, we have shown in previous
experiments, that there are no residual feeder cells (i.e.
Ia-bearing APC) remaining at the time our T cell lines are
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assayed date not shown) This suggests that the
responses are also not Ia-dependent. However, based on
the findings of Suzuki et al. (1986), it might still be
postulated that Ia was playing a role in our responses.
As suggested by Suzuki et al. (1986), such a role of Ia
determinants may occur by passive acquisition of Ia
(secreted by other cells) by T cells. Thus, it is
possible that our responder lines were reacting to Ia
passively acquired by our irradiated T cell lines/clones.
We think this explanation is unlikely in light of our
results showing varied patterns of responses of the
responder lines towards various stimulators. As seen in
Table IV, some of the responder lines were stimulated best
by PPD-lines or equally well by both 8BO and PPD-clones,
or somewhat better by 8BO. These patterns suggest that,
the response of our lines to passively acquired Ia is
unlikely to explain all of the responses noted. It is
likely that other T cell surface determinants (possibly in
combination with passively acquired Ia) are the relevant
determinants in the stimulation of our responder lines.
Our studies indicated an unusual pattern of suppres-
sion when 8BO or F128 was used as stimulator in the
presence of PMBP. When A4 was cultured with PMBP there
was a small response noted (Table VIII and IX). This
response may have been due to a small contamination of A4
with irradiated 8BO that was nevertheless able to escape
the effects of the irradiation and to proliferate in
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culture. However, when A4 was cultured with 8BO or F128
together with PMBP, a decreased proliferative response was
noted. This surprising PMBP-related suppression was not
noted when A4 was stimulated with a PPD-specific clones
together with PPD. However, there was a small decrease in
proliferation noted when A4 responded to an OVA-clone in
the presence of ovalbumin. The mechanisms underlying this
suppression are not yet clear. One possible explanation
would involve an antigen-induced increase in IL-2
receptors on the irradiated stimulators resulting in a
increased adsorption of responder-secreted IL-2 on the
irradiated stimulators. This could theoretically decrease
the proliferative response o f the responder lines.
However, the lack of a suppressive response noted with the
PPD-clones together with PPD argues against this
explanation.
Although we found that line A4 was a phenotypic
helper cell, it was still possible that it could have
suppressive effects in vivo. In fact, Ellerman et al.
(1988) generated T suppressor cells in rats that were
strongly CD4+ but became transiently CD8+ when activated.
The activation-dependent co-expression of CD4 and CD8
cell-surface markers has been described for both human and
rat polyclonal T-cell populations (Blue et al., 1985; Blue
et al., 1986; Green and Jotte, 1985) Human T suppressor
clones have been described that co-express the CD4 and CD8
antigens (Ottenhoff et al., 1986). We found that the A4
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line did not protect syngeneic recipients from 8BO line
mediated EAE when injected simultaneously with 8BO.
Despite our in vitro proliferation assays showing that A4
responds to PMBP, the in vivo test indicated that when
injected alone, A4 does not mediate EAE.
We found that by increasing the amount of A4 we may
have accelerated the disease onset. However, since only a
limited number of experiments were performed, we will have
to use different concentrations of responder and EAE-
mediating lines in future experiments. Because of the
surprising suppression noted in vitro in the presence of
PMBP, in the second in vivo experiment we injected the
lines together with PMBP. We postulated that this
addition might lead to the secretion of suppressor factors
in vivo. As noted above, this did not yield a suppressive
effect, but rather an enhancing effect was seen. The part
played by the PMBP in this effect cannot be evaluated at
this time. Finally, as seen in Tables IX and X, the PPD-
specific line seemed to lessen the clinical signs of EAE
when coinj ected with 8BO. This effect has been seen
occasionally (but variably) by our laboratory and is
presently being studied.
In summary, these studies we have generated data
suggesting a novel type of T cell-T cell interaction
occurring between two IL-2 dependent T cell lines.
Futhermore, while such interactions do not appear to be T
cell receptor-specific, we have nevertheless demonstrated
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that relevant specific antigen is able to inhibit certain,
but not all of these lines. Future studies will involve
the elucidation of the part played by Ia determinants in
these reactions. In addition, the antigen-mediated
inhibition of these T-T reactions will be further studied.
CONCLUSIONS
i. We have been able to generate responder T cells that
proliferate to both the immunized line 8BO and to other
unrelated lines.
2. The results indicate that the responses of some
responder T cell lines to stimulator T cell lines did not
require antigen presenting cells.
While the specific determinant recognized by our
responder line has not been determined, we have found that
the response of the responder lines to PMBP-specific lines
can be inhibited by PMBP. However, the response of the
responder line to a PPD-specific line could not be
inhibited by PPD.
4. The results demonstrate that the A4 line, which is
reactive to the MBP-specific line 8BO, express surface
markers typical of helper cells (L3T4+).
5. In vivo, the responder line A4 did not protect
syngeneic normal recipients from the EAE-mediating line,
8BO.
6. In the future, additional in vitro studies
characterizing the determinant s recognized by our
responder lines will be performed. Further in vivo
studies will also be undertaken.
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